Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers

  • Jacobs Cachá, Concepció
  • Vergara Arana, Ander
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
  • López Hellin, Joan
  • Soler Romeo, Maria Jose
  • Ariceta Iraola, Gema
Biomarcadors; Algoritme de diagnosi; Glomerulosclerosi segmentària focal, Biomarcadores; Algoritmo de diagnóstico; Glomeruloesclerosis segmentaria focal, Biomarkers; Diagnosis algorithm; Focal segmental glomerulosclerosis, Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, Instituto de Salud Carlos III (PI17/00257, PI18/01704 and PI18/01832) and REDinREN (RD16/0009/0030).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection

  • Carrera Muñoz, Claudia
  • Font Miñarro, Cristina
  • Juvé Torres, Mariona
  • Castañeda Amado, Zaira Ivette
  • Torres, Irina B.
  • Casanova, Franc
  • Gabaldon, Maria Alejandra
  • Alvarez, Tiffany
  • Cantenys, Sergi
  • KERVELLA, Delphine
  • Meneghini, Maria
  • Crespo, Elena
  • Zamora Carrillo, Jorge Ivan
  • Patricio-Liébana, Marc
  • Sellarès , Joana
  • Perelló, Manel
  • Martínez Gallo, Mónica
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Donor-derived cell-free DNA; Rejection, Biomarcadores; ADN libre de células derivado de donantes; Rechazo, Biomarcadors; ADN lliure de cèl·lules derivat de donants; Rebuig, Donor-derived cell-free deoxyribonucleic acid (DNA) (dd-cfDNA) and urinary chemokines are promising noninvasive biomarkers for kidney allograft rejection, but direct comparative data are lacking. In this prospective pilot study, we analyzed 194 biopsies (101 for-cause, 93 surveillance) paired with dd-cfDNA and urinary chemokine (CXCL9, CXCL10, CCL2, VEGF-A) concentrations in kidney transplant recipients. We evaluated their correlation, diagnostic accuracy for rejection phenotypes, and integration into diagnostic models with clinical and immunologic variables. Rejection was diagnosed in 32.5% of biopsies, predominantly antibody-mediated. dd-cfDNA showed strong diagnostic performance in both for-cause (area under the receiver operating characteristic curve [AUC] 0.85) and surveillance (AUC 0.91) biopsies. Conversely, urinary chemokines, particularly the composite Score4, showed accuracy mainly in for-cause biopsies (AUC 0.76). Remarkably, Score4 combined with donor-specific antibodies showed similar performance as dd-cfDNA + donor-specific antibodies (AUC 0.90) in for-cause biopsies. Internal bootstrap validation, including calibration metrics, confirmed the consistency of the models. dd-cfDNA provides robust diagnostic accuracy for kidney allograft rejection across distinct clinical settings. Urinary chemokine measures, especially Score4, may offer valuable diagnostic utility in for-cause biopsies. These findings support context-specific integration of noninvasive biomarkers and represent the first direct comparison of dd-cfDNA and urinary chemokines, informing personalized approaches to rejection monitoring., The results reported in this manuscript were supported by competitive research grants from the Instituto de Salud Carlos III (isciii) PI18/01832, PI23/01909, PI22/00749, PI22/01019, RICORS2040-Renal (Redes de Investigación Cooperativa Orientadas a Resultados en Salud financed by Instituto Salud Carlos III and cofinanced by the European Union (O.B.), RD21/0005/0016) and European Union (ERDF/ESF)-A way to build Europe (O.B.).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Challenges in primary focal segmental glomerulosclerosis diagnosis, from the diagnostic algorithm to novel biomarkers

  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Vergara, Ander|||0000-0003-1926-0147
  • García-Carro, Clara|||0000-0002-5130-603X
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Moreso, Francesc|||0000-0002-7267-3963
  • Seron, Daniel|||0000-0003-2054-653X
  • López-Hellín, Joan|||0000-0001-7286-3882
  • Soler, María José|||0000-0003-3621-0766
Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30-50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers

  • Jacobs Cachá, Concepció
  • Vergara Arana, Ander
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
  • López Hellin, Joan
  • Soler Romeo, Maria Jose
  • Ariceta Iraola, Gema
Biomarcadors; Algoritme de diagnosi; Glomerulosclerosi segmentària focal, Biomarcadores; Algoritmo de diagnóstico; Glomeruloesclerosis segmentaria focal, Biomarkers; Diagnosis algorithm; Focal segmental glomerulosclerosis, Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, Instituto de Salud Carlos III (PI17/00257, PI18/01704 and PI18/01832) and REDinREN (RD16/0009/0030).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection

  • Carrera Muñoz, Claudia
  • Font Miñarro, Cristina
  • Juvé Torres, Mariona
  • Castañeda Amado, Zaira Ivette
  • Torres, Irina B.
  • Casanova, Franc
  • Gabaldon, Maria Alejandra
  • Alvarez, Tiffany
  • Cantenys, Sergi
  • KERVELLA, Delphine
  • Meneghini, Maria
  • Crespo, Elena
  • Zamora Carrillo, Jorge Ivan
  • Patricio-Liébana, Marc
  • Sellarès , Joana
  • Perelló, Manel
  • Martínez Gallo, Mónica
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Donor-derived cell-free DNA; Rejection, Biomarcadores; ADN libre de células derivado de donantes; Rechazo, Biomarcadors; ADN lliure de cèl·lules derivat de donants; Rebuig, Donor-derived cell-free deoxyribonucleic acid (DNA) (dd-cfDNA) and urinary chemokines are promising noninvasive biomarkers for kidney allograft rejection, but direct comparative data are lacking. In this prospective pilot study, we analyzed 194 biopsies (101 for-cause, 93 surveillance) paired with dd-cfDNA and urinary chemokine (CXCL9, CXCL10, CCL2, VEGF-A) concentrations in kidney transplant recipients. We evaluated their correlation, diagnostic accuracy for rejection phenotypes, and integration into diagnostic models with clinical and immunologic variables. Rejection was diagnosed in 32.5% of biopsies, predominantly antibody-mediated. dd-cfDNA showed strong diagnostic performance in both for-cause (area under the receiver operating characteristic curve [AUC] 0.85) and surveillance (AUC 0.91) biopsies. Conversely, urinary chemokines, particularly the composite Score4, showed accuracy mainly in for-cause biopsies (AUC 0.76). Remarkably, Score4 combined with donor-specific antibodies showed similar performance as dd-cfDNA + donor-specific antibodies (AUC 0.90) in for-cause biopsies. Internal bootstrap validation, including calibration metrics, confirmed the consistency of the models. dd-cfDNA provides robust diagnostic accuracy for kidney allograft rejection across distinct clinical settings. Urinary chemokine measures, especially Score4, may offer valuable diagnostic utility in for-cause biopsies. These findings support context-specific integration of noninvasive biomarkers and represent the first direct comparison of dd-cfDNA and urinary chemokines, informing personalized approaches to rejection monitoring., The results reported in this manuscript were supported by competitive research grants from the Instituto de Salud Carlos III (isciii) PI18/01832, PI23/01909, PI22/00749, PI22/01019, RICORS2040-Renal (Redes de Investigación Cooperativa Orientadas a Resultados en Salud financed by Instituto Salud Carlos III and cofinanced by the European Union (O.B.), RD21/0005/0016) and European Union (ERDF/ESF)-A way to build Europe (O.B.).